Search
Tilactase
go.drugbank.com/drugs/DB13761ApprovedInvestigationalTilactase is a beta-D-galactosidase obtained from Aspergillus oryzae. It is produced as a chewable tablet that has to be taken before the consumption of a lactose-containing meal. The beta-D-galactosidase us a large monomeric multi-domai...
Cetrimonium
go.drugbank.com/drugs/DB01718ApprovedInvestigationalCetrimonium is a quaternary ammonium cation whose salts are used as antiseptics.
Synonyms: N,N,N-Trimethyl-1-hexadecanaminiumCategories: Compounds used in a research, industrial, or household settingBurosumab
go.drugbank.com/drugs/DB14012ApprovedInvestigationalBurosumab (KRN23) is an entirely human monoclonal IgG1 antibody that binds excess fibroblast growth factor 23 (FGF23) and has been successfully tested in clinical trials in children with X-linked hypophosphatemic … Food and Drug Administration approved Crysvita (burosumab) in April 2018.
Ambrosia artemisiifolia pollen
go.drugbank.com/drugs/DB10385ApprovedAmbrosia artemisiifolia pollen is mainly used in allergenic testing.
Trastuzumab emtansine
go.drugbank.com/drugs/DB05773ApprovedInvestigationalTrastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent … Trastuzumab emtansine is marketed under the brand name Kadcyla and is indicated for use in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic
Lorpiprazole
go.drugbank.com/drugs/DB09195ApprovedLorpiprazole is a serotonin antagonist and reuptake inhibitor used for the treatment of major depressive disorder. It is a piperazinyl-triazole derivative.
Mesoridazine
go.drugbank.com/drugs/DB00933ApprovedWithdrawnA phenothiazine antipsychotic with effects similar to chlorpromazine.
NS-2359
go.drugbank.com/drugs/DB05805InvestigationalThis mode of action is expected to produce an optimal reduction in all disease symptoms and the possibility of an earlier onset of action compared to antidepressants already on the market.
Ergoloid mesylate
go.drugbank.com/drugs/DB01049Approved[L2639]Later in 1991, the mixture of ergoloid mesylates was retaken by Sun Pharmaceutical Industries and approved by the FDA. … Ergoloid Mesylate is an equiproportional preparation of three different ergotamantriones: dihydroergocornine, dihydroergocristine, and dihydroergocryptine.
TTP889
go.drugbank.com/drugs/DB05131InvestigationalTTP889, an orally bioavailable selective inhibitor of the intrinsic coagulation pathway, is being developed as an anticoagulant for the treatment of thromboembolic disorders. … TTP889 has proven to be effective in preventing clot formation in several animal models of human disease, without any signs of the bleeding associated with traditional anticoagulants.